NZ630248A - Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{ [(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({ (1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl} carbamoyl)pyrrolidin-1-yl]carbonyl} -2,2-dimethylpropyl]carbamate - Google Patents
Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{ [(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({ (1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl} carbamoyl)pyrrolidin-1-yl]carbonyl} -2,2-dimethylpropyl]carbamateInfo
- Publication number
- NZ630248A NZ630248A NZ630248A NZ63024813A NZ630248A NZ 630248 A NZ630248 A NZ 630248A NZ 630248 A NZ630248 A NZ 630248A NZ 63024813 A NZ63024813 A NZ 63024813A NZ 630248 A NZ630248 A NZ 630248A
- Authority
- NZ
- New Zealand
- Prior art keywords
- carbamoyl
- mono
- propylene glycol
- chain fatty
- ethenylcyclopropyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261643454P | 2012-05-07 | 2012-05-07 | |
| PCT/US2013/038770 WO2013169520A1 (en) | 2012-05-07 | 2013-04-30 | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ630248A true NZ630248A (en) | 2016-11-25 |
Family
ID=48428670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ630248A NZ630248A (en) | 2012-05-07 | 2013-04-30 | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{ [(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({ (1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl} carbamoyl)pyrrolidin-1-yl]carbonyl} -2,2-dimethylpropyl]carbamate |
Country Status (33)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019130341A1 (en) * | 2017-12-26 | 2019-07-04 | Hetero Labs Limited | Capsule compositions comprising lopinavir and ritonavir |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150119317A1 (en) * | 2012-05-07 | 2015-04-30 | Bristol-Myers Squibb Company | Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
| JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| NZ767340A (en) | 2018-03-14 | 2025-11-28 | Kandy Therapeutics Ltd | Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
| CN1240437C (zh) * | 2000-10-31 | 2006-02-08 | 贝林格尔·英格海姆药物公司 | 口服的自乳化的吡喃酮蛋白酶抑制剂制剂 |
| US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| TWI480272B (zh) * | 2008-10-09 | 2015-04-11 | Anadys Pharmaceuticals Inc | 藉由５，６－二氫－１ｈ－吡啶－２－酮與一或多種其他抗病毒化合物的組合物抑制ｃ型肝炎病毒的方法 |
| US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
-
2013
- 2013-04-29 US US13/872,652 patent/US20130302414A1/en not_active Abandoned
- 2013-04-30 WO PCT/US2013/038770 patent/WO2013169520A1/en not_active Ceased
- 2013-04-30 AU AU2013260005A patent/AU2013260005B2/en not_active Ceased
- 2013-04-30 PL PL13722217T patent/PL2846780T3/pl unknown
- 2013-04-30 LT LTEP13722217.0T patent/LT2846780T/lt unknown
- 2013-04-30 HR HRP20181583TT patent/HRP20181583T1/hr unknown
- 2013-04-30 JP JP2015511510A patent/JP6276756B2/ja not_active Expired - Fee Related
- 2013-04-30 RS RS20181141A patent/RS57881B1/sr unknown
- 2013-04-30 MY MYPI2014703294A patent/MY171378A/en unknown
- 2013-04-30 EA EA201492039A patent/EA028749B1/ru not_active IP Right Cessation
- 2013-04-30 BR BR112014027676A patent/BR112014027676A2/pt not_active IP Right Cessation
- 2013-04-30 PE PE2014001988A patent/PE20142439A1/es not_active Application Discontinuation
- 2013-04-30 MX MX2014013220A patent/MX358545B/es active IP Right Grant
- 2013-04-30 DK DK13722217.0T patent/DK2846780T3/en active
- 2013-04-30 PT PT13722217T patent/PT2846780T/pt unknown
- 2013-04-30 EP EP13722217.0A patent/EP2846780B1/en active Active
- 2013-04-30 CA CA2872765A patent/CA2872765A1/en not_active Abandoned
- 2013-04-30 NZ NZ630248A patent/NZ630248A/en not_active IP Right Cessation
- 2013-04-30 ES ES13722217.0T patent/ES2688817T3/es active Active
- 2013-04-30 SI SI201331126T patent/SI2846780T1/sl unknown
- 2013-04-30 KR KR20147033971A patent/KR20150004921A/ko not_active Ceased
- 2013-04-30 CN CN201380023724.1A patent/CN104363899A/zh active Pending
- 2013-04-30 SG SG11201406964QA patent/SG11201406964QA/en unknown
- 2013-04-30 SM SM20180506T patent/SMT201800506T1/it unknown
- 2013-05-06 TW TW102116102A patent/TWI577392B/zh not_active IP Right Cessation
- 2013-05-06 UY UY0001034785A patent/UY34785A/es unknown
- 2013-05-06 AR ARP130101544A patent/AR090954A1/es unknown
-
2014
- 2014-10-27 PH PH12014502405A patent/PH12014502405A1/en unknown
- 2014-11-03 IL IL235466A patent/IL235466B/en active IP Right Grant
- 2014-11-06 CL CL2014003012A patent/CL2014003012A1/es unknown
- 2014-12-02 CO CO14265249A patent/CO7141457A2/es unknown
- 2014-12-05 ZA ZA2014/08967A patent/ZA201408967B/en unknown
-
2018
- 2018-10-15 CY CY181101051T patent/CY1120756T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019130341A1 (en) * | 2017-12-26 | 2019-07-04 | Hetero Labs Limited | Capsule compositions comprising lopinavir and ritonavir |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ630248A (en) | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{ [(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({ (1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl} carbamoyl)pyrrolidin-1-yl]carbonyl} -2,2-dimethylpropyl]carbamate | |
| PH12021550328A1 (en) | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject | |
| MX2021002553A (es) | Metodos para reducir el riesgo de eventos cardiovasculares en un sujeto. | |
| MX2015002239A (es) | Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares. | |
| WO2014074552A3 (en) | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy | |
| MX352299B (es) | Aerosoles y geles en humedo transparentes. | |
| IN2014DN08449A (enExample) | ||
| EP4338805A3 (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| NZ618734A (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
| AR095182A1 (es) | Composiciones de estatinas y ácidos grasos omega-3 | |
| ATE394365T1 (de) | Verfahren zur synthese von verbindungen vom ceramidtyp | |
| CR20230147A (es) | Preparación y almacenamiento de formulaciones de rna liposomal adecuadas para terapia | |
| CO2021011652A2 (es) | Ésteres de ácido graso como agentes anti-malassezia | |
| ECSP099039A (es) | Esteres de dha y su utilización en el tratamiento y la prevención de enfermedades cardiovasculares | |
| WO2013009800A3 (en) | Compositions of alkylating agents and methods of treating skin disorders therewith | |
| IN2015DN04151A (enExample) | ||
| HK1210417A1 (en) | Compositions, methods and/or devices for prevention and/or treatment of dry eye disorders | |
| WO2011090333A3 (ko) | 클로린 유도체와 불포화 지방산의 접합체, 이를 함유하는 광감작제, 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료용 조성물 | |
| MX369742B (es) | Formulación de liberación modificada. | |
| MX2009009838A (es) | Esteres de acidos grasos de glucocorticoides como agentes antiinflamatorios y anti-cancer. | |
| WO2011143271A3 (en) | Therapeutic liposomes and methods for producing and using the same | |
| WO2012075093A3 (en) | Topical formulations for administration of omega-3 fatty acids | |
| EP4364810A3 (en) | Topical formulations and uses thereof | |
| MX2007007859A (es) | Composiciones comestibles las cuales comprenden un lipido primario, un co-lipido y un ingrediente fisiologicamente activo lipofilico y agua, y su preparacion. | |
| RU2009107155A (ru) | Антиоксидантное лекарственное средство на основе спиртовых отходов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: BRISTOL-MYERS SQUIBB HOLDING, CH Effective date: 20150212 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2018 BY CPA GLOBAL Effective date: 20170418 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2019 BY CPA GLOBAL Effective date: 20180316 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2020 BY CPA GLOBAL Effective date: 20190314 |
|
| LAPS | Patent lapsed |